← All trials
NCT05065372
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2022
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Oct 4, 2021
- Last posted
- Oct 27, 2021
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Colorado, DenverLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.